Analyst
Needham & Company
Equibles does not estimate personal net worth.
John is recorded as Analyst at Needham & Company. John has spoken on 4 earnings calls across 4 companies, most recently for Amphastar Pharmaceuticals, Inc. on August 6, 2026. Those appearances were for Amphastar Pharmaceuticals, Inc. (AMPH), Evolus, Inc. (EOLS), Heron Therapeutics, Inc. (HRTX) and CorMedix Inc. (CRMD). The companies whose calls John spoke on are classified in the Healthcare sector.
“So just a couple on your current product portfolio. The first being the generic Atrivant launch that came about in mid-April. I believe you've highlighted previously that you see this product capturing as much as 50% to 80% of the market.”
“So first I wanted to kind of follow up on the last question and look to the second half of the year. You know, you guys are coming off a solid first half and updating, you know, your full year guidance.”
“First, if I could just follow up on Zinrilif again with regard to the 1Q Winter Storm headwinds. Just curious if you could quantify the impact with regard to surgical volumes for the quarter there.”
“So first, just curious if you have any updates on the inpatient opportunity with DEF and CAS, you know, have the size of the current contributions been growing, and just curious what growth profile you see from this segment in 26 and 27.”
Needham & Company
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
EOLS
Drug Manufacturers - Specialty & Generic · Healthcare
CRMD
Biotechnology · Healthcare
